Diagnostic efficiency of miR-21 and miR-34a serum levels in malign and benign prostate diseases
- 22 October 2021
- journal article
- research article
- Published by Pera Yayıncılık Hizmetleri in Yeni Üroloji Dergisi
- Vol. 16 (3) , 221-227
Abstract
Objective: In this study aimed to determine the diagnostic efficiency of miR-21 and miR-34a serum levels in the discrimination of benign prostatic hyperplasia, chronic prostatitis, and prostate cancer. Materials and Methods: Blood samples were taken from 70 patients (25 benign prostatic hyperplasias, 10 chronic prostatitides, and 35 prostate cancer) who underwent prostate needle biopsy. After obtaining serum under suitable conditions, RNA isolation, cDNA synthesis, and qRT-PCR analysis were performed using Qiagen brand kits on Rotor-Gene® Q (Qiagen, Germany) device. -∆Ct values were calculated using RNU6 as a reference gene for normalization. -∆Ct values were used in all statistical calculations. Results: It was observed that miR-21 serum levels were upregulated in chronic prostatitis and cancer groups compared to benign prostatic hyperplasia and the difference between the groups was statistically significant (p = 0.021 and p = 0.001, respectively). The specificity and sensitivity of miR-21 and miR-21/miR-34a combination was calculated as 56% and 86%; 84% and 71% in discriminating benign prostatic hyperplasia and prostate cancer groups, respectively. Conclusion: In this study, it has been shown that miR-21 and miR-21/miR-34a combination has diagnostic performance that can be a biomarker candidate in diagnosing prostate cancer. In addition, the presence of a gradual increase in chronic prostatitis and prostate cancer at miR-21 levels compared to benign prostatic hyperplasia suggests that inflammation and cancer transformation processes taking place at the molecular level are also reflected in the circulating microRNA profile. Keywords: Prostate cancer, Prostatitis, Benign prostatic hyperplasia, MicroRNA, Diagnostic efficiencyKeywords
This publication has 16 references indexed in Scilit:
- Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learnedNature Reviews Clinical Oncology, 2018
- Trends in incidence and 5‐year mortality in men with newly diagnosed, metastatic prostate cancer—A population‐based analysis of 2 national cohortsCancer, 2018
- Clinical implications of PTEN loss in prostate cancerNature Reviews Urology, 2018
- miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental studyAsian Pacific Journal of Tropical Medicine, 2017
- 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate CancerNew England Journal of Medicine, 2016
- Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancerTumor Biology, 2014
- MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory responseProceedings of the National Academy of Sciences, 2012
- Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancerTumor Biology, 2011
- miR-21: An Androgen Receptor–Regulated MicroRNA that Promotes Hormone-Dependent and Hormone-Independent Prostate Cancer GrowthCancer Research, 2009
- Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or LowerJAMA, 2005